Skip to main content
Log in

Pharmacological Treatment of Psychiatric Disorders in Children and Adolescents

Focus on Guidelines for the Primary Care Practitioner

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

This article is a practical review of the current psychopharmacological agents used in the treatment of child and adolescent psychiatric disorders. Psychostimulants such as methylphenidate, dexamphetamine and pemoline are effective in the control of symptoms associated with attention deficit hyperactivity disorder. The controlled release preparations and the adjunctive use of clonidine are helpful to extend stimulant effects and control adverse effects. Tricyclic antidepressants are helpful in individual cases of child and adolescent depression, but adverse effects may limit their use. Clomipramine has been found to be effective for childhood obsessive-compulsive disorder. Selective serotonin (5-HT) reuptake inhibitors (SSRIs) appear to be safer for depression and are also useful in obsessive-compulsive disorder. Buspirone is effective for the treatment of anxiety disorders in children. Newer atypical antipsychotics such as risperidone may have less limiting adverse effects than older antiychotics in the treatment of psychosis and severe behaviour disorders, but the physician must be vigilant for the emergence of tardive dyskinesia. Drug treatment in children and adolescents must take into account the child’s environmental influences and be part of an overall treatment plan where individual, familial and cultural issues are addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Institute of Medicine. Research on children and adolescents with mental, behavioral and developmental disorders. Washington (DC): National Academy Press, 1989

    Google Scholar 

  2. Offord DR, Boyle MH, Fleming JE, et al. Ontario Child Health Study: summary of selected results. Can J Psychiatry 1989; 34: 483–91

    PubMed  CAS  Google Scholar 

  3. Koplewicz HS, Williams DT. Psychopharmacological treatment. In: Kestenbaum CJ, Williams DT, editors. Handbook of clinical assessment of children and adolescents. Vol. 2. New York (NY): New York University Press, 1988

    Google Scholar 

  4. Dulcan MK. Using psychostimulants to treat behavioral disorders of children and adolescents. J Child Adolesc Psychopharmacol 1990; 1: 7–20

    Article  PubMed  CAS  Google Scholar 

  5. Simeon JG, Wiggins DM. Pharmacotherapy of attention-deficit hyperactivity disorder. Can J Psychiatry 1993; 38: 443–8

    PubMed  CAS  Google Scholar 

  6. Gadow KD, Nolan EE, Sverd J, et al. Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry 1990; 29: 710–8

    Article  PubMed  CAS  Google Scholar 

  7. Kaplan SL, Busner J, Kupietz S, et al. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADHD: a preliminary report. J Am Acad Child Adolesc Psychiatry 1990; 29: 719–23

    Article  PubMed  CAS  Google Scholar 

  8. Shekim WO. Diagnosis and treatment of attention deficit and conduct disorders in children and adolescents. In: Simeon JG, Ferguson HB, editors. Treatment strategies in child and adolescent psychiatry. New York (NY): Plenum Press, 1990

    Google Scholar 

  9. Ross RB, Licamele WL. Slow-release methylphenidate: problems when children chew tablets. J Clin Psychiatry 1984; 45: 525

    Google Scholar 

  10. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine and pemoline. Pediatrics 1990; 86: 226–37

    PubMed  Google Scholar 

  11. Sallee FR, Stiller RL, Perel JM. Pharmacodynamics of pemoline in attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 244–51

    Article  PubMed  CAS  Google Scholar 

  12. Nehra A, Mullick F, Ishak KG, et al. Pemoline-associated hepatic injury. Gastroenterol 1990; 99: 1517–9

    CAS  Google Scholar 

  13. Jaffe SL. Pemoline and liver function [letter]. J Am Acad Child Adolesc Psychiatry 1989; 28: 457–8

    Article  PubMed  CAS  Google Scholar 

  14. Greenhill LL. Treatment issues in children with attention-deficit hyperactivity disorder. Psychiatr Ann 1989; 119: 604–13

    Google Scholar 

  15. Satterfield JH, Cantwell DP, Schell A, et al. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 1982; 39: 486–7

    Google Scholar 

  16. Mattes J, Gittelman R. Growth of hyperactive children on maintenance methylphenidate. Arch Gen Psychiatry 1983; 30: 317–21

    Article  Google Scholar 

  17. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992; 15: 191–222

    PubMed  CAS  Google Scholar 

  18. Waters BG. Psychopharmacology of the psychiatric disorders of childhood and adolescence. Med J Aust 1990; 152: 32–9

    PubMed  CAS  Google Scholar 

  19. Fulton AI, Yates WR. Family abuse of methylphenidate. Am Fam Physician 1988; 38: 143–5

    PubMed  CAS  Google Scholar 

  20. Lowe TL, Cohen DJ, Friedhoff AJ, et al. Stimulant medication precipitates Tourette’s syndrome. JAMA 1982; 247: 1729–31

    Article  PubMed  CAS  Google Scholar 

  21. Calis KA, Grothe DR, Elia J. Attention deficit hyperactivity disorder. Clin Pharmacol 1990; 9: 632–42

    CAS  Google Scholar 

  22. Comings DE, Comings BG. A controlled study of Tourette syndrome: I. Attention deficit disorder, learning disorders and school problems. Am J Hum Genet 1987; 41: 701–41

    PubMed  CAS  Google Scholar 

  23. Konkol RJ, Fischer M, Newby RF. Double-blind, placebo-controlled stimulant trial in children with Tourette’s syndrome and attention-deficit hyperactivity disorder. Ann Neurol 1990; 28: 424

    Google Scholar 

  24. Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings. J Am Acad Child Adolesc Psychiatry 1992; 31: 462–70

    Article  PubMed  CAS  Google Scholar 

  25. Rapoport JL, Castellanos FX. Stimulant drug treatment in children with Tourette’s syndrome and attention deficit hyperactivity disorder. Clin Neuropharmacol 1992; 15 Suppl. 1: 226A

    Article  Google Scholar 

  26. Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994; 33: 424–6

    Article  PubMed  CAS  Google Scholar 

  27. Ambrosini P, Bianchi M, Rabinovitch H, et al. Antidepressant treatments in children and adolescents. J Child Adolesc Psychiatry 1993; 32: 1–6

    Article  CAS  Google Scholar 

  28. Biederman J, Baldessarini R, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 1989; 28: 903–11

    Article  PubMed  CAS  Google Scholar 

  29. Ryan ND. Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol 1990; 1: 2

    Article  Google Scholar 

  30. Riddle MA, Geller B, Ryan N. Case study. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32: 792–7

    Article  PubMed  CAS  Google Scholar 

  31. Popper C. Balancing knowledge and judgement: a clinician looks at new developments in child and adolescent psychopharmacology. Child Adolesc Clin North Am 1995; 4(2): 487

    Google Scholar 

  32. Biederman J, Baldessarini RJ, Goldblatt A, et al. A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32: 805–13

    Article  PubMed  CAS  Google Scholar 

  33. Wilens TE, Biederman J, Geist DE, et al. Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993; 32: 343–9

    Article  PubMed  CAS  Google Scholar 

  34. Garfinkel B, Wender P, Sloman L, et al. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 1983; 22: 343–8

    Article  CAS  Google Scholar 

  35. Flament MF, Rapoport JL, Berg CZ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry 1985; 42: 977–83

    Article  PubMed  CAS  Google Scholar 

  36. Simeon JG, Ferguson HB, DiNicola VF, et al. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacpl Biol Psychiatry 1990; 14: 791–5

    Article  CAS  Google Scholar 

  37. Emslie G. The AACAP News. J Am Acad Child Adolesc Psychiatry 1996; Jan-Feb: 15

  38. Barrickman L, Noyes R, Kuperman S, et al. Treatment of ADHD with fluoxetine: a preliminary trial. J Am Acad Child Adolesc Psychiatry 1991; 30: 762–7

    PubMed  CAS  Google Scholar 

  39. Gammon G, Brown T. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharm 1993; 3(1): 1–10

    Article  CAS  Google Scholar 

  40. Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 1062–9

    Article  PubMed  CAS  Google Scholar 

  41. King RA, Riddle MA, Chapell PB, et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991; 30: 179–86

    Article  PubMed  CAS  Google Scholar 

  42. Apter A, Ratzoni G, King RA, et al. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 1994; 33: 342–8

    Article  PubMed  CAS  Google Scholar 

  43. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55 Suppl. A: 6–22

    PubMed  Google Scholar 

  44. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 649–57

    Article  PubMed  CAS  Google Scholar 

  45. Simeon JG, Ferguson HB, Van Wyck Fleet V. Bupropion effects in attention deficit and conduct disorders. Can J Psychiatry 1986; 31: 581–5

    PubMed  CAS  Google Scholar 

  46. Trott GE, Friese HJ, Menzel M, et al. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacol 1992; 106: S134–6

    Article  Google Scholar 

  47. Reiter S, Kutcher S, Gardner D. Anxiety disorders in children and adolescents: clinical and related issues in pharmacological treatment. Can J Psychiatry 1992; 37: 432–8

    PubMed  CAS  Google Scholar 

  48. Realmuto GL, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989; 9: 122–5

    Article  PubMed  CAS  Google Scholar 

  49. Kutcher SP, Reiter S, Gardner DM, et al. The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatr Clin North Am 1992; 15: 41–67

    PubMed  CAS  Google Scholar 

  50. Kranzler HR. Use of buspirone in an adolescent with overanxious disorder. J Am Acad Child Adolesc Psychiatry 1988; 27: 789–90

    Article  PubMed  CAS  Google Scholar 

  51. Simeon JG. Buspirone effects in adolescent psychiatric disorders. Eur Neuropsychopharmacol 1991; 1: 421

    Article  Google Scholar 

  52. Simeon JG, Knott VJ, Dubois C, et al. Buspirone therapy of mixed anxiety disorders in childhood and adolescence: a pilot study. J Child Adolesc Psychopharmacol 1994; 4: 159–70

    Article  Google Scholar 

  53. Kutcher SP, Mackenzie S. Successful clonazepam treatment of adolescents with panic disorder. J Clin Psychopharmacol 1988; 8: 229

    Article  Google Scholar 

  54. Coffey BJ. Anxiolytics for children and adolescents: traditional and new drugs. J Child Adolesc Psychopharmacol 1990; 1: 57–83

    Article  PubMed  CAS  Google Scholar 

  55. Simeon JG. Use of anxiolytics in children. Encephale 1993; 9: 71–4

    Google Scholar 

  56. Simeon JG. Pediatric psychopharmacology. Can J Psychiatry 1989; 34: 115–22

    PubMed  CAS  Google Scholar 

  57. Campbell M, Gonzalez NM, Ernst M, et al. Antipsychotics. In: Werry JS, Aman GA, editors. Practitioner’s guide to psychoactive drugs for children and adolescents. New York (NY): Plenum Press, 1993: 269–96

    Chapter  Google Scholar 

  58. Gualtieri CT, Quade D, Hicks RE, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984; 141: 20–3

    PubMed  CAS  Google Scholar 

  59. Sloman L. Use of medication in pervasive developmental disorders. Psych Clin North Am 1991; 14(1): 165–82

    CAS  Google Scholar 

  60. Cohen D, Riddle M, Leckman J. Pharmacotherapy of Tourette’s disorder. Psychiatr Clin North Am 1992 Mar; 15: 1

    Google Scholar 

  61. Simeon JG, Carrey NJ, Wiggins DM, et al. Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychiatry 1995; 5: 69–79

    Google Scholar 

  62. Mandoki MW. Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 1995; 5: 49–67

    Article  Google Scholar 

  63. Birmaher B, Baker R, Kapur S, et al. Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1992; 31: 160–4

    Article  PubMed  CAS  Google Scholar 

  64. Frazier JA, Gordon CT, McKenna K, et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994; 33: 658–63

    Article  PubMed  CAS  Google Scholar 

  65. Carlson GA. Bipolar disorders in children and adolescents. In: Garfinkel B, Carlson G, Weller E, editors. Psychiatric disorders in children and adolescents. Philadelphia (PA): WB Saunders, 1990

    Google Scholar 

  66. Alessi N, Naylor M, Ghaziuddin M, et al. Update on lithium carbonate therapy in children and adolescents. J Am Acad Child Adolesc Psychiatry 1994; 33: 291–304

    Article  PubMed  CAS  Google Scholar 

  67. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate. Arch Gen Psychiatry 1984; 41: 650–6

    Article  PubMed  CAS  Google Scholar 

  68. Papatheodorou G, Kutcher S, Katic M, et al. The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J Clin Psychopharmacol 1995 Apr; 15: 110–6

    Article  PubMed  CAS  Google Scholar 

  69. Popper C. Introduction: therapeutic empiricism and therapeutic basics. J Child Adolesc Psychopharmacol 1990; 1: 3–5

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carrey, N.J., Wiggins, D.M. & Milin, R.P. Pharmacological Treatment of Psychiatric Disorders in Children and Adolescents. Drugs 51, 750–759 (1996). https://doi.org/10.2165/00003495-199651050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651050-00004

Keywords

Navigation